ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

With an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now looks like it may be able to add lung, stomach and colorectal cancer to its approved indications.